Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.

ABSTRACT: The use of rapamycin to extend lifespan and delay age-related disease in mice is well-established despite its potential to impair glucose metabolism which is driven partially due to increased hepatic gluconeogenesis. We tested whether a combination therapeutic approach using rapamycin and metformin could diminish some of the known metabolic defects caused by rapamycin treatment in mice. In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment. In female mice, this defect was alleviated over time by simultaneous treatment with metformin, also by diet, such that females treated with both drugs where indistinguishable from cont

SUBMITTER: Weiss R 

PROVIDER: S-EPMC5892694 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature